Elekta presents brain data. Elekta stock gains 1.53 percent

Published on 10/05/2026 at 11:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 3.00 percent to SEK 3.54 billion in fiscal 2026/27 first quarter. Elekta stock costs EUR 4.66 on October 5, 2026 after EUR 4.59.

Moderner Bestrahlungsraum mit High-Tech-Linearbeschleuniger in blauem Klinik-Ambiente — Fotorealistischer Bestrahlungsraum zeigt Elekta AB SE0000163628 mit modernem Linearbeschleuniger in klinischer High-Tech-Umgebung, Illustration mit AI erstellt.

Elekta (ISIN SE0000163628) was trading at EUR 4.66 at Lang & Schwarz on October 5, 2026 at 11:11 a.m. CEST, up 1.53 percent versus the prior close of EUR 4.59. On September 29, 2026, Elekta reported new phase 2 data on Leksell Gamma Knife treatment for patients with up to 50 brain metastases, giving the stock a clinical-data headline alongside its improving profitability profile.

Gamma Knife data adds a clinical signal

The September 29 release concerns cognitive outcomes in patients treated with Leksell Gamma Knife. The company also listed an ASTRO study on September 28 covering long-term outcomes for localized pancreatic cancer treated with Elekta Unity, broadening the recent evidence base for its oncology portfolio.

Elekta is listed on Nasdaq Stockholm under ticker EKTA B.ST, according to Global Banking and Finance. The company develops medical technology for cancer treatment and brain disorders, with radiotherapy, radiosurgery and treatment software at the center of its offering.

Margins outpaced revenue

In the first quarter of fiscal 2026/27, revenue fell 3.00 percent year over year to SEK 3.54 billion from SEK 3.65 billion, according to Stocksentinel. The same report says adjusted gross margin expanded to 42.60 percent from 37.00 percent, a 5.60 percentage-point increase.

Adjusted EBIT rose 68.00 percent to SEK 395.00 million, producing an adjusted EBIT margin of 11.20 percent. Management reiterated fiscal 2026/27 guidance for 2.00 percent to 4.00 percent constant-currency sales growth and a 12.50 percent to 13.50 percent adjusted EBIT margin, with more than SEK 500.00 million in annualized savings.

Analysts flag execution risks

UBS maintained a sell recommendation and a SEK 41.00 price target on September 8, 2026, according to MarketScreener. The bank cited China, US competition and cost inflation, while noting that China represents 13.00 percent of Elekta revenue.

The contrast is clear: first-quarter revenue contracted, but adjusted profitability improved sharply. For investors, the next test is whether the margin gains and savings can translate into stronger installations and recurring service growth.

Next report is November 25

Elekta's investor calendar lists November 25, 2026, for the second-quarter fiscal 2026/27 report. The company had a market capitalization of SEK 20.1 billion on October 5, 2026, while the Lang & Schwarz quote was EUR 4.66, up 1.53 percent from the EUR 4.59 prior close dated October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Elekta stock.